Vall Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), Barcelona,
Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Neuroendocrinology. 2019;108(1):18-25. doi: 10.1159/000493319. Epub 2018 Aug 28.
Unmet medical needs are not infrequent in oncology, and these needs are usually of higher magnitude in rare cancers. The field of neuroendocrine neoplasms (NENs) has evolved rapidly during the last decade, and, currently, a new WHO classification is being implemented and several treatment options are available in the metastatic setting after the results of prospective phase III clinical trials. However, several questions are still unanswered, and decisions in our daily clinical practice should be made with limited evidence. In the 2016 meeting of the advisory board of the European Neuroendocrine Tumor Society (ENETS), the main unmet medical needs in the metastatic NENs setting were deeply discussed, and several proposals to try to solve them are presented in this article, including biomarkers, imaging, and therapy.
在肿瘤学领域,未满足的医疗需求并不罕见,而在罕见癌症中,这些需求通常更为突出。神经内分泌肿瘤(NENs)领域在过去十年中发展迅速,目前正在实施新的世卫组织分类,并且在几项前瞻性 III 期临床试验的结果后,在转移性环境中提供了几种治疗选择。然而,仍有几个问题尚未得到解答,我们在日常临床实践中的决策应基于有限的证据。在欧洲神经内分泌肿瘤学会(ENETS)顾问委员会 2016 年的会议上,深入讨论了转移性 NENs 环境中的主要未满足的医疗需求,并在本文中提出了一些尝试解决这些问题的建议,包括生物标志物、成像和治疗。